United Health Products partners with NAMSA to sponsor CelluSTAT hemostatic gauze clinical study

• United Health Products signed an agreement with NAMSA, which will sponsor a new clinical study of CelluSTAT Hemostatic Gauze.
• NAMSA will seek an Investigational Device Exemption to organize the human study of the company’s neutralized cellulose hemostat technology.
• UHP will receive an exclusive right of reference to the study data for use in a revised Premarket Approval application.
• The study is intended to proceed while UHP works with the FDA to resolve an outstanding Warning Letter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Health Products Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001477932-26-004244), on July 10, 2026, and is solely responsible for the information contained therein.